The Zhitong Finance App learned that Weilizhibo-B (09887) opened nearly 3% higher. As of press release, it had risen 2.44% to HK$63, with a turnover of HK$4,586,400.

^{According to the news, on September 14, Weilizhibo-B issued an announcement in the form of an oral report at the 2026 World Lung Cancer Conference (WCLC 2026) to release updated phase II clinical research data on first-line treatment of patients with non-small cell lung cancer (NSCLC) with the self-developed drug Virixine® (opatisumimab, PD-L1/4-1BB) combined with chemotherapy on the first-line treatment of patients with non-small cell lung cancer (NSCLC).} According to the updated data, an unprecedented high remission rate was shown, and almost consistent clinical benefits were observed in patients with squamous NSCLC PD-L1 negative (PD-L1 tumor ratio score (TPS) < 1%) and positive (PD-L1 TPS ≥ 1%), while patients with non-squamous NSCLC PD-L1 TPS ≥ 1% received deep and long-lasting tumor remission.

^{As the world's first PD-L1/4-1BB bispecific antibody that has entered the marketing license review stage, Velisign® uses a differentiated dual action mechanism to achieve deeper curative response and broader clinical benefits, and further continues this advantage based on the established long-term survival benefits of first-generation tumor immunotherapy.} Currently, Verisign ^® is undergoing clinical research on 14 solid tumor indications, and there is growing evidence as a pan-tumor immunotherapy (IO) 2.0 cornerstone therapy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.